Overview

A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

Status:
Completed
Trial end date:
2018-02-12
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company